Tcr2 Therapeutics — Merger or Acquisition (March 2023)
36 slides from Tcr2 Therapeutics's merger presentation, Mar 6, 2023
Slide 1: Creating a preeminent cell therapy company
C reating a preeminent cell therapy company Leading T he C ancer R evoluti on
Slide 2: Disclaimer
2 Disclaimer This communication relates to the proposed transaction pursuant to the terms of the Agreement and Plan of Merger, dated March 5 , 2023 , by and among Adaptimmune Therapeutics plc (“Parent”), CM Merger Sub, Inc . (“Merger Sub”), and TCR² Therapeutics Inc . (the “Company”) . This communic
Slide 3: Creating a preeminent cell therapy company
C reating a preeminent cell therapy company Leading T he C ancer R evoluti on
Slide 4: Strategic combination transaction details
4 Terms/Ownership • Stock for stock transaction • Adaptimmune shareholders will own ~75% of the combined company • TCR 2 stockholders will own ~25% of the combined company Cash Position • Cash runway for combined company extended into 2026* Assets • Clinical programs targeting MAGE - A4 and mesothel
Slide 5: Strategic combination creates a preeminent cell therapy company
5 Solid tumors represent ~90% of all cancers Solid tumor focus Potential products in indications for MAGE - A4 and mesothelin Multiple near - term catalysts New targets: PRAME and CD70; Next - gen toolbox Significant operational benefits Innovative pipeline End - to - end capabilities Extended runwa
Slide 6: Cell and gene therapies set to transform the treatment landscape
6 0 5000 10000 15000 20000 25000 30000 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Sales at 10Y ~ $25B 0 5000 10000 15000 20000 25000 30000 2017 2018 2019 2020 2021 e2022 e2023 e2024 e2025 e2026 Peak sales >$70B (2019); remain steady in 2022 Cell and gene therapies set to transform the tr
Slide 7: Cell therapy solid tumor space: a significant opportunity
7 90% US cancer deaths from solid tumors Cell therapy solid tumor space: a significant opportunity 10% US deaths from blood cancers Ref: ACS Cancer Statistics 2020 All approved CAR - T therapies Solid tumors unaddressed opportunity for cell therapies
Slide 8: Complementary platforms drive broad access to solid tumors
8 Complementary platforms drive broad access to solid tumors Clinically validated cell therapies in solid tumors all utilize the full TCR complex Single - domain antibody, fused to the CD3 - epsilon leveraging endogenous TCR signalling ε δ α β γ ε TRuC - T Cell SPEAR T - cell Platform proprietary en
Slide 9: Clinical and preclinical pipeline targets: MAGE-A4, PRAME, MSLN
9 MAGE - A4 PRAME MSLN (Mesothelin) Pursuing: Synovial Sarcoma (BLA submission complete mid - 2023) Head & Neck (H&N) (Expansion Ph 1 cohort initiating) Urothelial (Expansion Ph 1 cohort initiating) Ovarian (Ph 2) Pursuing: Ovarian (Ph 2) Potential in: Mesothelioma (Ph 1 and 2) Pancreatic (Ph 1
Slide 10: Deep pipeline of opportunities with two clinical franchises
10 PROGRAM TRIAL NAME(S)/ INDICATION(S)/DESIGN IND - ENABLING PHASE 1 PHASE 2/3 afami - cel MAGE - A4 SPEARHEAD - 1 pivotal trial Synovial Sarcoma ADP - A2M4CD8* MAGE - A4 SURPASS Ph 1 signal finding trial Endometrial, Ovarian, Esophageal , EGJ, Gastric, Melanoma, NSCLC , H&N, Urothelial Two arms: M
Slide 11: Compelling efficacy across MAGE-A4 and mesothelin franchises
11 Compelling efficacy across MAGE - A4 and mesothelin franchises • Median Duration 50.3 weeks • Potential to be 1 st new drug approved for synovial sarcoma in more than 10 years ~39% ORR in synovial sarcoma • Tumor Regression in 93% of heavily pretreated patients • Ovarian: 2 PRs; 6/7 Tumor Regress
Slide 12: Funded to deliver on multiple value creating catalysts
12 Funded to deliver on multiple value creating catalysts 2023 2024 afami - cel • BLA submission completion (synovial sarcoma). Expected mid - year • Potential afami - cel PDUFA/FDA approval ; if approved would be the first marketed engineered TCR T - cell therapy for a solid tumor indication ADP -
Slide 13: Innovative toolbox to improve depth and durability of responses
13 *Noile - Immune ** Alpine Immune Sciences • CD8 • Checkpoint inhibitors • IL15 • IL7 + CCL19* Persistence, trafficking T - cell effectiveness • PD - 1 switch • Checkpoint inhibitors • dnTGFbeta • SiP and TiP technology** Overcoming tumor microenvironment • Overlapping target screening (e.g., MAGE
Slide 14: Company combines specialized cell therapy capabilities for success
14 US Philadelphia, PA and Cambridge, MA • TRuC research • Autologous cell manufacturing • Clinical development • Translational sciences UK Oxford and Stevenage • TCR and allogeneic research • Vector m anufacturing • Allogeneic manufacturing v Company combines specialized cell therapy capabilities f
Slide 15: Combined company will have extended runway into 2026
15 Combined company will have extended runway into 2026* Strong balance sheet extending the runway into 2026 to finance multiple catalysts* * Following closing of the transaction, the combined company is anticipated to have a cash runway into 2026
Slide 16: Strategic combination creates a preeminent cell therapy company
16 Solid tumors represent ~90% of all cancers Solid tumor focus Potential products in indications for MAGE - A4 and mesothelin Multiple near - term catalysts New targets: PRAME and CD70; Next - gen toolbox Significant operational benefits Innovative pipeline End - to - end capabilities Extended runw
Slide 17: Appendix
Appendix
Slide 18: TCR programs Targeting MAGE-A4
TCR programs Targeting MAGE - A4
Slide 19: afami-cel
afami - cel
Slide 20: Advanced autologous engineered TCR program targeting MAGE-A4
20 Advanced autologous engineered TCR program targeting MAGE - A4 MRCLS: myxoid/round cell liposarcoma; NSCLC: non - small cell lung cancer 1. Mortality figures based on American Cancer Society 2022 (US) and Global Can (EU4/UK 2020) 2. MAGE - A4 expression based on ADAP samples and expression cut of
Slide 21: Afami-cel in Synovial Sarcoma - Response rate 38.6%, Duration 50 weeks
21 Afami - cel in Synovial Sarcoma - Response rate 38.6%, Duration 50 weeks Data cut - off August 29, 2022. Cohort 1 data. Data represent percent changes from baseline in sum of diameters ( SLD for non - nodal lesions and short axis for nodal lesions) in target lesions through progression or prior t
Slide 22: Rolling BLA submission to be completed by mid-2023
22 Rolling BLA submission to be completed by mid - 2023 Preclinical Module Submission Clinical Module Submission CMC Module Submission Q4 2022 Q1 2023 Mid 2023 x Module submitted • FDA agreed that the clinical package supports submission of the BLA • Submission to include updated SPEARHEAD - 1 (pivo
Slide 23: ADP-A2M4CD8
ADP - A2M4CD8
Slide 24: ADP-A2M4CD8 – SURPASS family of trials
24 ADP - A2M4CD8 – SURPASS family of trials * Mortality figures based on American Cancer Society 2022 (US) and Global Can (EU4/UK 2020) MAGE - A4 expression based on ADAP samples and expression cut off criteria of ≥30% tumor cells at ≥2+ intensity. Synovial sarcoma and MRCLS MAGE - A4 expression bas
Slide 25: Results consistent: 37% response rate in SURPASS Ph1 trial
25 Results consistent: 37% response rate in SURPASS Ph 1 trial Data cut - off: Nov. 23, 2022; CR=complete response: PR=partial response; SD=stable disease; PD=progressive disease Weeks from SPEAR T - cell infusion • 52% response rate in focus areas of ovarian, urothelial, and head & neck cancers (13
Slide 26: SURPASS Phase 1: ADP-A2M4CD8 monotherapy or with nivolumab
26 SURPASS Phase 1 (NCT04044859): ADP - A2M4CD8 TCR T - cell therapy as monotherapy or in combination with nivolumab Focus on patients with urothelial carcinoma, head and neck carcinoma, ovarian carcinoma Patients with esophageal , esophagogastric junction, or gastric carcinoma, non - small cell lun
Slide 27: SURPASS new H&N cohort: first-line with pembrolizumab
27 SURPASS Phase 1 (NCT04044859) new H&N cohort: First - line ADP - A2M4CD8 TCR T - cell therapy in combination with pembrolizumab In patients with unresectable locally advanced or newly metastatic H&N tumors with CPS≥1 CPS, combined positive score; H&N, head and neck; SOC, standard of care
Slide 28: SURPASS new urothelial cohort: second-line with pembrolizumab
28 SURPASS Phase 1 (NCT04044859) new urothelial cohort: Second - line ADP - A2M4CD8 TCR T - cell therapy in combination with pembrolizumab following first - line cisplatin - based chemotherapy In patients with unresectable, locally advanced, or newly metastatic urothelial tumors SOC, standard of car
Slide 29: SURPASS-3: Randomized ADP-A2M4CD8 alone or with nivolumab
29 SURPASS - 3 Phase 2 (NCT05601752): Randomized ADP - A2M4CD8 TCR T - cell therapy alone or in combination with nivolumab In patients with recurrent ovarian carcinoma ECOG, Eastern Cooperative Oncology Group
Slide 30: TRuC programs Targeting Mesothelin (MSLN)
TR u C programs Targeting Mesothelin (MSLN)
Slide 31: Autologous engineered TRuC program targeting Mesothelin
31 Pha autologous engineered TR u C program targeting Mesothelin *Refs: Inaguma 2017, SEER Statistics, Morello 2016, Tozbikian 2014 NSCLC Non - small cell lung cancer • Expression levels ranging from ~20% to ~76% 2 across tumors including: ~ 58% of Ovarian cancer patients • Others include: • Pancrea
Slide 32: Consistent tumor regression in patients with gavo-cel
32 48 26 - 4 - 4 - 5 - 5 - 6 - 8 - 8 - 9 - 10 - 10 - 11 - 12 - 13 - 16 - 18 - 20 - 21 - 22 - 25 - 25 - 39 - 49 - 56 - 61 - 64 - 66 - 67 - 80 -100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 10 29 30 28 7 27 32 19 34 9 11 21 25 16 12 20 18 1 31 6 8 13 22 33 14 5 3 15 2 4 Change in Target Les
Slide 33: Improving gavo-cel efficacy: anti-PD1 combination and TC-510
33 Improving gavo - cel efficacy: combination with anti - PD1 and next - gen enhancements (TC - 510) PD - 1 Re - invigorate TRuC - T cells gavo - cel + anti - PD1 Enhances gavo - cel and TILs in the tumor microenvironment Reverts T cell exhaustion PD - 1 CD28 PD1xCD28 Maintenance of T cell potency P
Slide 34: Preclinical Programs Targeting PRAME and CD70
Preclinical Programs Targeting PRAME and CD70
Slide 35: Preclinical autologous engineered TCR program targeting PRAME
35 1. Mortality figures based on American Cancer Society 2022 (US) and Global Can (EU4/UK 2020) ; PRAME Expressi on data source: Qiagen Oncoland TCGA_B38 NSCLC Non - small cell lung cancer Preclinical a utologous engineered TCR program targeting PRAME • Clinically validated “clean” target; member of
Slide 36: Targeting CD70: next-gen approach to attractive target
36 TC - 520 targeting CD70: Next - gen approach to attractive target x Versatile target expressed in: • hematological malignancies: acute myeloid leukemia (AML), lymphoma • solid tumors: renal cell carcinoma (RCC), x Expression in normal cells limited to a subset of activated T - cells, B - cells an
TCR2 Therapeutics — Merger or Acquisition (March 2023) on 6ix